Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical company integrating the R&D, manufacturing, and sales of drugs. As a principal subsidiary of Hansoh Pharma (03692.HK), the Company is committed to improving human health through continuous innovation, focusing mainly on the fields of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases. The Company has maintained its position for a number of consecutive years in the Top 100 Pharmaceutical Companies in the global market and in the top 3 among China’s Best Industrial Enterprises in the Pharmaceutical R&D Pipeline, and is a key national high-tech enterprise and national technological innovation demonstration enterprise.

    

Expand outstanding R&D capabilities with over 20 years of R&D experience, the Company has established a number of state-level R&D centers, such as National Enterprise Technology Centers, Postdoctoral Research Stations, and State Key Laboratories. The Company has highly efficient capabilities in the discovery of innovative drugs, with R&D efforts covering the fields of peptides, biologics, small molecules, ADC drugs, siRNAs and different modalities related platforms. The Company has commenced 60 major national scientific and technological projects; has won two gold medals in China Patent Awards and two prestige prizes in the National Scientific and Technological Progress Awards. Hansoh has also been granted more than 600 invention patents in China and abroad; and has participated in establishing more than 200 national pharmaceutical standards.

To date, over 50 clinical studies for 30 innovative drugs in different clinical development stages are currently being carried out by the Company, forming a rich and competitive R&D pipeline. Currently, the Company has six independently-developed Class 1 innovative drugs have been approved for marketing, the only globally-approved EPO mimetic peptide Saint Luolai (Pegmolesatide Injection), China's first independently-developed third-generation EGFR-TKI AMEILE (Almonertinib Mesylate Tablets), China's first independently-developed oral antiviral drug for hepatitis B Hengmu (Tenofovir Amibufenamide Tablets), China's independently-developed novel second-generation TKI for chronic myeloid leukemia Hansoh Xinfu (Flumatinib Mesylate Tablets), China's first independently-developed innovative GLP-1RA weekly formulation Fulaimei (Polyethylene Glycol Loxenatide Injection), and a new third-generation nitroimidazole drug, Mailingda (Morinidazole and Sodium Chloride Injection), all of which have been included in the National Reimbursement Drug List, aiming to effectively reduce the burden for patients. In 2023, the proportion of innovative drugs and collaborative products revenue increased to 67.9%. This indicates that Jiangsu Hansoh Pharma is committed and has transformed into an innovative biopharma company focusing on the development and marketing of innovative drugs.

Jiangsu Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and using advanced production equipment. Our production quality system has been officially certified by FDA in the United States, EMA of the European Union, and PMDA in Japan, and finished preparations and APIs have been approved for marketing in Europe, America, Japan, etc.

Looking ahead, Jiangsu Hansoh Pharma will further deepen its innovation-driven strategy, targeting the unmet clinical needs of Chinese and international patients, and develop more innovative drugs to improve the quality of human life.